Alyeska Investment Group L.P. Invests $770,000 in Genelux Corporation $GNLX

Key Points

• Alyeska Investment Group L.P. acquired a new stake in Genelux Corporation, purchasing 285,000 shares valued at approximately $770,000, bringing their ownership to 0.76%.
$1.95 and a high of $5.89, with a market capitalization of $127.28 million.
• Analysts have a consensus rating of "Buy" for Genelux, with a target price of $20.33, indicating significant upside potential.

Alyeska Investment Group L.P. bought a new position in Genelux Corporation (NASDAQ:GNLX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 285,000 shares of the company's stock, valued at approximately $770,000. Alyeska Investment Group L.P. owned about 0.76% of Genelux as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of GNLX. Advisor Resource Council purchased a new position in Genelux during the first quarter valued at approximately $34,000. Miracle Mile Advisors LLC increased its position in Genelux by 60.0% in the first quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company's stock worth $108,000 after purchasing an additional 15,000 shares during the last quarter. Liberty Wealth Management LLC bought a new stake in Genelux in the first quarter worth $45,000. Raymond James Financial Inc. bought a new stake in Genelux in the fourth quarter worth $41,000. Finally, 5T Wealth LLC bought a new stake in Genelux in the first quarter worth $49,000. Hedge funds and other institutional investors own 37.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on GNLX shares. Wall Street Zen raised shares of Genelux from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. HC Wainwright reiterated a "buy" rating on shares of Genelux in a report on Wednesday, July 23rd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $20.33.

Genelux Price Performance

NASDAQ GNLX traded up $0.30 during mid-day trading on Friday, hitting $3.95. The stock had a trading volume of 294,287 shares, compared to its average volume of 119,978. The firm's 50 day moving average is $3.44 and its 200 day moving average is $3.10. Genelux Corporation has a twelve month low of $1.95 and a twelve month high of $5.89. The stock has a market capitalization of $149.19 million, a price-to-earnings ratio of -4.59 and a beta of -0.33.

Genelux (NASDAQ:GNLX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.02. As a group, equities research analysts expect that Genelux Corporation will post -0.88 earnings per share for the current year.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.